Terminal β-galactose–containing cell-surface glycans

Terminal β-galactose–containing cell-surface glycans are a diverse class of carbohydrate structures found on the surface of mammalian cells, where a galactose residue in the β-configuration occupies the non-reducing terminus of the glycan chain (NIH, 2023). These glycans are typically found on N-linked and O-linked glycoproteins, as well as glycolipids like gangliosides (MDPI, 2024). In healthy tissues, these residues are often masked by terminal sialic acids; however, in pathological states such as cancer, desialylation or aberrant glycosylation leads to their exposure (NIH, 2021). These exposed glycans serve as critical ligands for galectins, a family of endogenous lectins that regulate immune responses, cell adhesion, and apoptosis (NIH, 2023). In oncology, terminal β-galactose (notably the Thomsen-Friedenreich antigen) is a well-known tumor-associated carbohydrate antigen (TACA) involved in metastasis and immune evasion (MDPI, 2024). Therapeutic strategies include galectin inhibitors to block these interactions, anti-glycan antibodies for direct tumor targeting, and enzyme-based approaches to either expose or degrade these structures in diseases like GM1-gangliosidosis (Frontiers, 2022; NIH, 2019).

Other names

AsialoglycansGalactosylated glycansβ-galactoside-containing glycansThomsen-Friedenreich antigenTF antigenCD176T antigen

Drugs targeting these glycans typically act by either blocking their interaction with endogenous receptors (e.g., galectin inhibitors), directly binding to them to induce immune-mediated cell death (e.g., anti-TF antibodies), or enzymatically modifying them to alter cell signaling or prevent toxic accumulation (e.g., sialidases or enzyme replacement therapies) (NIH, 2023; MDPI, 2024).